EyePoint (EYPT) Interest Expenses (2018 - 2024)
EyePoint (EYPT) posted Interest Expenses of $32.9 million for Q1 2026, up 1332.32% sequentially from -$2.7 million in Q4 2025, and up 846.33% YoY from $3.5 million in Q1 2025.
Analysis
EyePoint (EYPT) Interest Expenses (2018 - 2024) Analysis & Trends
EyePoint has reported Interest Expenses for 16 years, with the latest figure at $32.9 million in Q1 2026.
- Quarterly Interest Expenses rose 846.33% year-over-year to $32.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.9 million (up 846.33% YoY) and the FY2025 annual result came in at $73.2 million, up 878.44% from the prior year.
- Interest Expenses climbed to $32.9 million in Q1 2026 per EYPT's latest filing, from -$2.7 million in the prior quarter.
- Over five years, Interest Expenses peaked at $72.4 million in Q2 2022 and troughed at -$2.7 million in Q4 2025.
- A 5-year average of $27.0 million and a median of $12.3 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 7872.91% in 2024, then plunged 481.0% in 2025.
- Over 5 years, Interest Expenses stood at $693000.0 in 2022, then retreated by 6.64% to $647000.0 in 2023, then climbed by 8.19% to $700000.0 in 2024, then slumped by 481.0% to -$2.7 million in 2025, then jumped by 1332.32% to $32.9 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $32.9 million, -$2.7 million, and $45.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 14,000.00 |
| Jun 30, 2023 | 435,000.00 |
| Mar 31, 2023 | 812,000.00 |
| Dec 31, 2022 | 781,000.00 |
| Sep 30, 2022 | 662,000.00 |
| Jun 30, 2022 | 552,000.00 |
| Mar 31, 2022 | 1.19 Mn |
| Dec 31, 2021 | 1.39 Mn |
| Sep 30, 2021 | 1.39 Mn |
| Jun 30, 2021 | 1.38 Mn |
| Mar 31, 2021 | 1.35 Mn |
| Dec 31, 2020 | 1.83 Mn |
| Sep 30, 2020 | 1.84 Mn |
| Jun 30, 2020 | 1.81 Mn |
| Mar 31, 2020 | 1.78 Mn |
| Dec 31, 2019 | 1.79 Mn |
| Sep 30, 2019 | 1.77 Mn |
| Jun 30, 2019 | 1.60 Mn |
| Mar 31, 2019 | 1.02 Mn |
| Dec 31, 2018 | 1.64 Mn |